Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.

Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, Kunitada S.

J Clin Pharmacol. 2015 Nov;55(11):1286-92. doi: 10.1002/jcph.540. Epub 2015 Jun 26.

2.

Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.

Ogata K, Shimizu T, Masumoto H, Oguma T, Sugiyama N, Kunitada S.

Thromb Res. 2015 Apr;135(4):594-601. doi: 10.1016/j.thromres.2014.12.028. Epub 2015 Jan 4.

PMID:
25700621
3.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.

Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S.

Thromb Haemost. 2012 May;107(5):925-36. doi: 10.1160/TH11-08-0566. Epub 2012 Mar 8.

PMID:
22398655
4.

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S.

Thromb Res. 2012 Apr;129(4):e77-82. doi: 10.1016/j.thromres.2011.07.026. Epub 2011 Aug 17.

PMID:
21851967
5.

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S.

Thromb Haemost. 2011 Jun;105(6):1080-90. doi: 10.1160/TH10-11-0705. Epub 2011 May 5.

PMID:
21544313
6.

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.

Samama MM, Kunitada S, Oursin A, Depasse F, Heptinstall S.

Thromb Res. 2010 Oct;126(4):e286-93. doi: 10.1016/j.thromres.2010.07.015.

PMID:
20807664
7.

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S.

Thromb Haemost. 2010 Sep;104(3):633-41. doi: 10.1160/TH10-01-0066. Epub 2010 Aug 5.

PMID:
20694273
8.

Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers.

Mendell J, Tachibana M, Shi M, Kunitada S.

J Clin Pharmacol. 2011 May;51(5):687-94. doi: 10.1177/0091270010370974. Epub 2010 Jun 9.

PMID:
20534818
9.

Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S.

J Clin Pharmacol. 2010 Jul;50(7):743-53. doi: 10.1177/0091270009351883. Epub 2010 Jan 15.

PMID:
20081065
10.

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.

Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ.

Thromb Haemost. 2007 Oct;98(4):883-8.

PMID:
17938815
11.

Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.

Becker RC, Alexander JH, Li Y, Robertson T, Kunitada S, Spencer FA, Yang H, Harrington RA.

J Thromb Thrombolysis. 2004 Dec;18(3):193-7.

PMID:
15815881
12.

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.

Becker RC, Alexander J, Li YF, Bovill E, Spencer FA, Robertson TL, Kunitada S, Dyke CK, Harrington RA.

Thromb Haemost. 2004 Dec;92(6):1229-31. No abstract available.

PMID:
15622616
13.

Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.

Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Saint-Jacques H, Chetcuti S, Burton JR, Buergler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA; XaNADU-PCI PILOT Investigators.

J Thromb Haemost. 2004 Feb;2(2):234-41.

14.

Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.

Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ.

Thromb Haemost. 2002 Nov;88(5):733-8.

PMID:
12428086
15.

First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.

Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA.

Circulation. 2002 May 21;105(20):2385-91.

16.

Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat.

Iba T, Kidokoro A, Fukunaga M, Fuse S, Suda M, Kunitada S, Hara T.

Shock. 2002 Feb;17(2):159-62.

PMID:
11837793
17.

[FXa inhibitor].

Kunitada S.

Tanpakushitsu Kakusan Koso. 2000 Apr;45(6 Suppl):1169-73. Review. Japanese. No abstract available.

PMID:
10771691
18.

A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.

Kaiser B, Paintz M, Scholz O, Kunitada S, Fareed J.

Thromb Res. 2000 Apr 15;98(2):175-85.

PMID:
10713319
19.
20.

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.

Murayama N, Tanaka M, Kunitada S, Yamada H, Inoue T, Terada Y, Fujita M, Ikeda Y.

Clin Pharmacol Ther. 1999 Sep;66(3):258-64.

PMID:
10511061
21.

DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.

Tanabe K, Morishima Y, Shibutani T, Terada Y, Hara T, Shinohara Y, Aoyagi K, Kunitada S, Kondo T.

Thromb Haemost. 1999 May;81(5):828-34.

PMID:
10365760
23.

Amino acids and peptides. XXVII. Solid phase synthesis of fibrinogen-related peptides with disulfide bond formed on solid support.

Kakiuchi M, Izuno Y, Maeda M, Ueda K, Fujiwara K, Kunitada S, Kawasaki K.

Chem Pharm Bull (Tokyo). 1996 May;44(5):1107-10.

PMID:
8689720
24.

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.

Hara T, Yokoyama A, Morishima Y, Kunitada S.

Thromb Res. 1995 Oct 1;80(1):99-104.

PMID:
8578544
25.

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.

Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA.

Circulation. 1995 Aug 1;92(3):485-91.

26.
27.

Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue.

Kerins DM, Roy L, Kunitada S, Adedoyin A, FitzGerald GA, Fitzgerald DJ.

Circulation. 1992 Feb;85(2):526-32. Erratum in: Circulation 1992 Aug;86(2):698.

PMID:
1370924
28.

A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy.

Masumura H, Kunitada S, Irie K, Ashida S, Abe Y.

Eur J Pharmacol. 1992 Jan 14;210(2):163-72.

PMID:
1350991
29.

A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.

Kerins DM, Shuh M, Kunitada S, Fitzgerald GA, Fitzgerald DJ.

J Pharmacol Exp Ther. 1991 Apr;257(1):487-92.

PMID:
1708425
30.

A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury.

Masumura H, Kunitada S, Irie K, Ashida S, Abe Y.

Eur J Pharmacol. 1991 Feb 14;193(3):321-7.

PMID:
2055246
31.

Functional and metabolic effects of bucladesine (dibutyryl cyclic AMP) in the working rat heart preparation: comparison with dopamine.

Hashimoto H, Kunitada S, Tamura K.

Arch Int Pharmacodyn Ther. 1989 Sep-Oct;301:200-14.

PMID:
2560364
32.

Adrenergic and cholinergic modulation of extracellular cyclic nucleotides.

Ui M, Honma M, Kunitada S, Okada F, Ide H, Hata S, Satoh T.

Adv Cyclic Nucleotide Res. 1980;12:25-35. No abstract available.

PMID:
6250359
33.

The plasma cyclic AMP response to catecholamines as potentiated by phentolamine in rats.

Kunitada S, Ui M.

Eur J Pharmacol. 1978 May 15;49(2):167-76.

PMID:
207536
34.

Increases in plasma cyclic AMP dependent on endogenous catecholamines.

Kunitada S, Honma M, Ui M.

Eur J Pharmacol. 1978 Mar 15;48(2):159-69.

PMID:
205422

Supplemental Content

Loading ...
Support Center